Effects of One - week Triple Therpy of Ranitidine Bismuth Citrate , Amoxicillin and Clarithromycin in Helicobacter pylori - related Peptic Ulcer Patients

Lee, Kang Moon; Lee, Dong Soo; Ahn, Byung Min; Song, Ho Jin; Kim, Sang Woo; Han, Seok Won; Chung, In Sik; Sun, Hee Sik; Park, Doo Ho

Abstract

BACKGROUND/AIMS: We performed this study to investigate the efficacy and safety of one-week triple therapy consisted of ranitidine bismuth citrate (RBC), amoxicillin and clarithromycin in the treatment of H. pylori-related peptic ulcers.
METHODS
Fifty patients with peptic ulcer and H. pylori infection were randomly divided into two groups. One group was administered with RBC 400 mg, amoxicillin 1 g, clarithromycin 500 mg twice daily (RAC group). The other group was administered with or omeprazole 20 mg, amoxicillin 1 g, clarithromycin 500 mg twice daily (OAC group). Four weeks after eradication therapy, H. pylori status, ulcer healing, histological improvement and side effects were assessed.
RESULTS
In the RAC group, the eradication rate was 80% (20/25) in the intention-to-treat (ITT) analysis and 95.2% (20/21) in the per protocol (PP) analysis. In the OAC group, the eradication rates in the ITT and PP analysis were 76% (19/25) and 86.4% (19/22), respectively. Ulcer healing rate of the RAC group was 94.7% in the PP analysis. The grade of gastritis was improved after treatment. No significant side effects were noticed in both groups.
CONCLUSIONS
One-week triple therapy of RBC, amoxicillin, clarithromycin is effective and well tolerated in eradicating H. pylori and healing peptic ulcers. The efficacy is comparable to one-week course of omeprazole-based triple therapy.